Evidence map›Paper›PMID 27213445›Full record

ReviewNutrients2016

The Possible Role of Flavonoids in the Prevention of Diabetic Complications.

Roberto Testa, Anna Rita Bonfigli, Stefano Genovese, Valeria De Nigris, Antonio Ceriello

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06005142 (Therapeutic Intervention of Nutraceutical Eriomin Associated with Metformin to Improve the Control of Hyperglycemia in Patients with Prediabetes), which is not on this map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06005142 naactive not recruitingnot on this mapstarted 2024, after this paper: background citation

Therapeutic Intervention of Nutraceutical Eriomin Associated with Metformin to Improve the Control of Hyperglycemia in Patients with Prediabetes: a Double-blind, Randomized, Placebo-controlled Crossover Clinical Trial

TypeinterventionalSponsorThais CesarRan2024 to 2024Enrolled80ConditionsPre-diabetesArmsEriomin, Washout, Placebo
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Current drug discovery technologies · 2024
    Review
  12. Article
  13. 'Oxidative stress'-A new target in the management of diabetes mellitus.Journal of family medicine and primary care · 2023
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Roberto TestaExperimental Models in Clinical Pathology, INRCA-IRCCS National Institute, Ancona I-60127, Italy. r.testa@inrca.it.
Anna Rita BonfigliScientific Direction, INRCA-IRCCS National Institute, Ancona I-60127, Italy. a.bonfigli@inrca.it.
Stefano GenoveseDepartment of Cardiovascular and Metabolic Diseases, IRCCS Multimedica, Sesto San Giovanni I-20099, Italy. stefano.genovese@multimedica.it.
Valeria De NigrisInsititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C/Rosselló, 149-153, 08036 Barcelona, Spain. vnigris@clinic.ub.es.
Antonio CerielloDepartment of Cardiovascular and Metabolic Diseases, IRCCS Multimedica, Sesto San Giovanni I-20099, Italy. aceriell@clinic.ub.es.
Istituti di Ricovero e Cura a Carattere Scientifico · ITCentro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESMultiMedica · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus is a disease that affects many metabolic pathways. It is associated with insulin resistance, impaired insulin signaling, β-cell dysfunction, abnormal glucose levels, altered lipid metabolism, sub-clinical inflammation and increased oxidative stress. These and other unknown mechanisms lead to micro- and macro-complications, such as neuropathy, retinopathy, nephropathy and cardiovascular disease. Based on several in vitro animal models and some human studies, flavonoids appear to play a role in many of the metabolic processes involved in type 2 diabetes mellitus. In this review, we seek to highlight the most recent papers focusing on the relationship between flavonoids and main diabetic complications.

Indexed as

DietAnimalsAnti-Inflammatory AgentsAntioxidantsDiabetes ComplicationsDiabetes Mellitus, Type 2FlavonoidsHumansHypoglycemic AgentsTreatment OutcomeAnti-Inflammatory AgentsAntioxidantsFlavonoidsHypoglycemic Agentsdiabetic complicationsflavonoidstype 2 diabetes mellitus

Identifiers

PMID27213445
PMCPMC4882722
OpenAlexW2405166166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.